Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Hydrochloride Anlotinib Combined With Concurrent Radiochemotherapy for Locally Advanced (Stage IB3 and IIA2-IVA) Cervical Cancer

NCT04772001 is registered in ClinicalTrials.gov with Zhongnan Hospital as lead sponsor.

NCT NCT04772001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04772001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Hydrochloride Anlotinib Combined With Concurrent Radiochemotherapy for Locally Advanced (Stage IB3 and IIA2-IVA) Cervical Cancer
Lead sponsor
Zhongnan Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
March 12, 2021
Completion date
January 31, 2026
Enrollment
53 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

angiogenesis, chemoradiotherapy, uterine cervical neoplasms